Further exploration on OR4D6 revealed that additional BC cell lines were also sensitive to its KD in the context of SRC-3 inhibition, pointing to OR4D6 as a potential anti-cancer therapeutic target and supports the evolving concept that ectopically expressed ORs are hijacked by cancer cells to drive growth factor signaling pathways34. This evidence concerns the gene NCOA3 and breast cancer.